This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Howard Stern, M.D., Ph.D.
Chief Scientific Officer at Fog Pharmaceuticals


Dr. Howard Stern is the Chief Scientific Officer of FogPharma, Inc in Cambridge, MA.  In this role, Dr. Stern oversees a talented scientific team that is advancing HeliconTM peptides towards a new and potentially broadly applicable therapeutic class.  He is an accomplished leader who has contributed to drug discovery and development programs across varied therapeutic modalities including small molecules, antibodies, engineered cellular therapies, and now peptides.  Prior to FogPharma, Dr. Stern held roles of increasing responsibility at Genentech, Infinity Pharmaceuticals, and Juno Therapeutics.  He earned an M.D. and a Ph.D. in Biochemistry from the University of Washington and is certified in Anatomic Pathology by the American Board of Pathology.

Agenda Sessions

  • Towards Universal Druggability with HeliconTM Peptides